NeuroBo Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, NeuroBo Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 1 currently recruiting 7 completed early-phase tilt upper quartile by trial count

NeuroBo Pharmaceuticals: 8 sponsored US clinical trials, 1 recruiting.

NeuroBo Pharmaceuticals sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypercholesteremia, with 1 trials.

Upper-quartile sponsor footprint

NeuroBo Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

First in Human Study in Subjects With Obesity, But Otherwise Healthy

NCT06252220
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815
COMPLETED Phase 1

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

NCT04705415
COMPLETED Phase 2

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

NCT04603924
COMPLETED Phase 2

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT02944383
COMPLETED Phase 2

A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

NCT02634151
COMPLETED Phase 2

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

NCT02722408
COMPLETED Phase 2

Study of DA-9801 to Treat Diabetic Neuropathy

NCT01822925

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 6

Therapeutic Areas

Hypercholesteremia 1
Diabetic Neuropathy 1
Obesity 1

What is open in the NeuroBo Pharmaceuticals pipeline

1 recruiting of 8 indexed (13% open); 7 completed (88%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Hypercholesteremia (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

NeuroBo Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

NeuroBo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%10%20%30%40% Total trials Recruiting share NeuroBo PharmaceuticalsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Addario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
NeuroBo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

NeuroBo Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this NeuroBo Pharmaceuticals page

8 registered trials is a research-attention snapshot, not an endorsement of NeuroBo Pharmaceuticals or any single study.

  • 1 of NeuroBo Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Hypercholesteremia is the condition NeuroBo Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypercholesteremia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

NeuroBo Pharmaceuticals pipeline card: 8 registered trials from official public datasets.Report a data error.